Results 1 to 10 of about 417,859 (136)

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Journal of Biomedical Science, 2022
The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics ...
Monika Kumari, Ruei-Min Lu, Mu-Chun Li, Jhih-Liang Huang, Fu-Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, Joyce Pei-Yi Yuan, Hsiao-Ling Chiang, Cheng-Pu Sun, I.-Jung Lee, Wen-Shan Li, Hsing-Pang Hsieh, Mi-Hua Tao, Han-Chung Wu   +16 more
doaj   +1 more source

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

Journal of Biomedical Science, 2023
Background The COVID-19 pandemic continues to pose a significant worldwide threat to human health, as emerging SARS-CoV-2 Omicron variants exhibit resistance to therapeutic antibodies and the ability to evade vaccination-induced antibodies.
Hsiao-Ling Chiang, Kang-Hao Liang, Ruei-Min Lu, Ting-Wen Kuo, Yi‑Ling Lin, Han-Chung Wu   +5 more
doaj   +1 more source

Antibody cocktail effective against variants of SARS-CoV-2

Journal of Biomedical Science, 2021
Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate.
Kang-Hao Liang, Pao-Yin Chiang, Shih-Han Ko, Yu-Chi Chou, Ruei-Min Lu, Hsiu-Ting Lin, Wan-Yu Chen, Yi-Ling Lin, Mi-Hua Tao, Jia-Tsrong Jan, Han-Chung Wu   +10 more
doaj   +1 more source

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

Journal of Biomedical Science, 2022
Background With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efficacy.
I-Jung Lee, Cheng-Pu Sun, Ping-Yi Wu, Yu-Hua Lan, I-Hsuan Wang, Wen-Chun Liu, Joyce Pei-Yi Yuan, Yu-Wei Chang, Sheng-Che Tseng, Szu-I Tsung, Yu-Chi Chou, Monika Kumari, Yin-Shiou Lin, Hui-Feng Chen, Tsung-Yen Chen, Chih-Chao Lin, Chi-Wen Chiu, Chung-Hsuan Hsieh, Cheng-Ying Chuang, Chao-Min Cheng, Hsiu-Ting Lin, Wan-Yu Chen, Fu-Fei Hsu, Ming-Hsiang Hong, Chun-Che Liao, Chih-Shin Chang, Jian-Jong Liang, Hsiu-Hua Ma, Ming-Tsai Chiang, Hsin-Ni Liao, Hui-Ying Ko, Liang-Yu Chen, Yi-An Ko, Pei-Yu Yu, Tzu-Jing Yang, Po-Cheng Chiang, Shang-Te Hsu, Yi-Ling Lin, Chong-Chou Lee, Han-Chung Wu, Mi-Hua Tao   +40 more
doaj   +1 more source

Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice

Heliyon, 2023
The COVID-19 pandemic continues to threaten human health worldwide as new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge. Currently, the predominant circulating strains around the world are Omicron variants, which can
Ruei-Min Lu, Kang-Hao Liang, Hsiao-Ling Chiang, Fu-Fei Hsu, Hsiu-Ting Lin, Wan-Yu Chen, Feng-Yi Ke, Monika Kumari, Yu-Chi Chou, Mi-Hua Tao, Yi-Ling Lin, Han-Chung Wu   +11 more
doaj   +1 more source

Antibody CDR amino acids underlying the functionality of antibody repertoires in recognizing diverse protein antigens

Scientific Reports, 2022
Antibodies recognize protein antigens with exquisite specificity in a complex aqueous environment, where interfacial waters are an integral part of the antibody–protein complex interfaces.
Hung-Pin Peng, Hung-Ju Hsu, Chung-Ming Yu, Fei-Hung Hung, Chao-Ping Tung, Yu-Chuan Huang, Chi-Yung Chen, Pei-Hsun Tsai, An-Suei Yang   +8 more
doaj   +1 more source

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Journal of Biomedical Science, 2022
The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public health crisis that demands the timely creation of new therapeutics and viral detection.
Yu-Chyi Hwang, Ruei-Min Lu, Shih-Chieh Su, Pao-Yin Chiang, Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, Tzung-Yang Hsieh, Han-Chung Wu   +8 more
doaj   +1 more source

Bridging the gap between emerging models and humans by learning from polio animal studies: A systematic review

Clinical and Translational Discovery, 2022
Disease modelling plays a fundamental role in biomedical research, even more in virology where the virus depends strictly on its host for replication. Although animal models are extensively used in virology, there is an increasing demand for animal‐free ...
Giulia Moreni, Ikrame Aknouch, Morris Ras, Lieke Brouwer, René Spijker, Carlemi Calitz, Koert J. Stittelaar, Adithya Sridhar, Katja C. Wolthers, Dasja Pajkrt   +9 more
doaj   +1 more source

Orally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogs

Biology Open, 2021
Branaplam is a therapeutic agent currently in clinical development for the treatment of infants with type 1 spinal muscular atrophy (SMA). Since preclinical studies showed that branaplam had cell-cycle arrest effects, we sought to determine whether ...
Diethilde Theil, Reginald Valdez, Katy Darribat, Arno Doelemeyer, Rajeev Sivasankaran, Andreas Hartmann   +5 more
doaj   +1 more source

Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants

Journal of Biomedical Science, 2022
Background The variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) harbor diverse spike (S) protein sequences, which can greatly influence the efficacies of therapeutics.
Shih-Han Ko, Wan-Yu Chen, Shih-Chieh Su, Hsiu-Ting Lin, Feng-Yi Ke, Kang-Hao Liang, Fu-Fei Hsu, Monika Kumari, Chi-Yu Fu, Han-Chung Wu   +9 more
doaj   +1 more source